Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HRMY 
Harmony Biosciences Holdings (HRMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: HRMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -22.35% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.90B USD | Price to earnings Ratio 13.22 | 1Y Target Price 51.89 |
Price to earnings Ratio 13.22 | 1Y Target Price 51.89 | ||
Volume (30-day avg) 761012 | Beta 0.82 | 52 Weeks Range 28.14 - 41.61 | Updated Date 03/30/2025 |
52 Weeks Range 28.14 - 41.61 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.36% | Operating Margin (TTM) 27.69% |
Management Effectiveness
Return on Assets (TTM) 13.17% | Return on Equity (TTM) 25.84% |
Valuation
Trailing PE 13.22 | Forward PE 9.34 | Enterprise Value 1615380829 | Price to Sales(TTM) 2.66 |
Enterprise Value 1615380829 | Price to Sales(TTM) 2.66 | ||
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA 6.92 | Shares Outstanding 57345600 | Shares Floating 44329878 |
Shares Outstanding 57345600 | Shares Floating 44329878 | ||
Percent Insiders 11.55 | Percent Institutions 97.69 |
Analyst Ratings
Rating 4.25 | Target Price 53.88 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Harmony Biosciences Holdings
Company Overview
History and Background
Harmony Biosciences Holdings, Inc. was founded in 2017. It focuses on developing and commercializing innovative therapies for patients with rare neurological diseases and other central nervous system (CNS) disorders.
Core Business Areas
- Narcolepsy: Development and commercialization of Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.
- Idiopathic Hypersomnia: Exploring the potential use of Wakix and other therapies for the treatment of idiopathic hypersomnia (IH) and other CNS disorders.
Leadership and Structure
Harmony Biosciences is led by CEO John Jacobs. The company has a board of directors and a management team responsible for overseeing various functions, including research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Wakix (pitolisant): Wakix is a selective histamine 3 (H3) receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. As of recent estimates, Wakix has been prescribed to over 4,000 patients and generates revenue of around $500 million annually. Competitors include Xyrem/Xywav (Jazz Pharmaceuticals) and Sunosi (Axsome).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the CNS disorder segment, is characterized by high R&D costs, stringent regulatory requirements, and significant market potential for innovative therapies. The narcolepsy and idiopathic hypersomnia market has strong growth potential.
Positioning
Harmony Biosciences is positioned as a leader in the narcolepsy treatment market with Wakix. They aim to expand into other CNS disorders like idiopathic hypersomnia. Competitive advantages include its H3 receptor mechanism of action and a focus on unmet medical needs.
Total Addressable Market (TAM)
The narcolepsy market is estimated to be worth several billion dollars. The potential market for idiopathic hypersomnia is also significant. Harmony Biosciences is well-positioned to capture a meaningful share of this market.
Upturn SWOT Analysis
Strengths
- Approved and commercialized product (Wakix)
- Strong focus on CNS disorders
- Experienced management team
- Growing revenue and profitability
Weaknesses
- Reliance on a single product (Wakix)
- Competition from established players
- Potential patent challenges
- Limited pipeline
Opportunities
- Expansion into new indications (e.g., idiopathic hypersomnia)
- Acquisition of new assets
- Geographic expansion
- Development of next-generation therapies
Threats
- Generic competition
- Regulatory changes
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- JAZZ
- AXSM
Competitive Landscape
Harmony Biosciences has a competitive advantage with Wakix's unique mechanism of action. However, Jazz Pharmaceuticals has a larger market share due to its established presence and products like Xyrem/Xywav. Axsome has launched Sunosi, a newer competitor in the narcolepsy market, and is developing treatments for other CNS conditions
Major Acquisitions
Epygenix Therapeutics, Inc.
- Year: 2024
- Acquisition Price (USD millions): 35
- Strategic Rationale: The acquisition of Epygenix Therapeutics, Inc. adds clemizole hydrochloride, an investigational product, to Harmony's pipeline. Clemizole is being studied for treatment of Dravet syndrome (DS).
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been strong due to the successful launch and commercialization of Wakix.
Future Projections: Analysts project continued revenue growth driven by Wakix sales and potential expansion into new indications. Financial analysts estimate earnings growth of between 10% and 20% per year over the next 5 years
Recent Initiatives: Recent initiatives include clinical trials for Wakix in idiopathic hypersomnia and exploration of strategic partnerships and acquisitions.
Summary
Harmony Biosciences is a growing company focused on CNS disorders. Wakix is a strong product, driving revenue. Expanding into new indications and managing competition are crucial. The company has a solid financial position but must diversify its product portfolio to mitigate risks.
Similar Companies
- JAZZ
- AXSM
- AVXL
- NEWR
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company press releases
- Third party market reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harmony Biosciences Holdings
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 2020-08-19 | President, CEO & Director Dr. Jeffrey M. Dayno M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 268 | |
Full time employees 268 | |||
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.